Paul Mampilly Identifies a Breakthrough Biotech Company

Paul Mampilly is an investment researcher with a long track record of identifying and profiting from cutting-edge technology firms and trends. In a recent report to investors, he points out that the field of medical technology is changing dramatically. We are all used to doctors that practice “one size fits all medicine.” They get a small data set from the patient, the symptoms and test results. Then they prescribe the standard medicine or surgery. However, Paul Mampilly says, this way of treating all patients the same is becoming as extinct as the dodo bird. Every patient is a unique individual, and so every medical solution needs to be individually tailored to each person, including their genomic profile. This is precision medicine.

He edits an investment newsletter called Profits Unlimited for Banyan Hill Publishing, which tells subscribers of the great companies he has found which are working in one of the great technological trends of the modern world. In a recent free report he tells how he has found a small biotech company which is leading the revolution in precision medicine. It’s working on one of the greatest medical breakthroughs in history.

Instead of giving all patients with a disease the same drug, doctors will look at the patient’s DNA and design a drug that treats the disease using the patient’s unique genetic profile. See, doctors used to think that all cases of a given disease were the same. They knew that not all patients responded to every drug, but they did the best they could with what they had. After the humane genome was sequenced, researchers began to understand that diseases are different at the genetic level. That’s why a medicine that cures one person’s sickness does nothing for somebody else. The company Paul Mampilly has identified will help doctors identify the DNA sequence of their patients.

Paul Mampilly has been an investing legend on Wall Street for over 25 years. He started out in 1991 at Bankers Trust as an assistant portfolio manager. As he demonstrated his ability to pick winning stocks, he went to work for Deutsche Bank and ING, managing accounts worth millions of dollars. Later he ran Kinetics Asset Management, increasing assets under management from $6 billion to $25 billion. He averaged 26% annual returns, and Barron’s called Kinetics one of the world’s best hedge funds. During the 2008-2009 financial crisis, he won the Templeton Foundation investment competition without selling anything short.

For details: